| ribavirin / Generic mfg. |
NCT00751426: Treatment of Hepatitis C in Psychiatric Patients |
|
|
| Completed | N/A | 81 | Europe | | Charite University, Berlin, Germany, Ludwig-Maximilians - University of Munich | Mental Disorders, Drug Addiction | 02/02 | 05/02 | | |
CIRES, NCT00422838: Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. |
|
|
| Completed | N/A | 20 | Europe | fine-needle aspiration biopsy | Foundation for Liver Research | Hepatitis C, Liver, Immunology, Regulation | 06/10 | 11/10 | | |
NCT00700401: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). |
|
|
| Completed | N/A | 262 | RoW | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 11/10 | 11/10 | | |
RE-CHUT, NCT00725842: Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) |
|
|
| Terminated | N/A | 97 | Europe | Peg-IFN alfa-2b, SCH 054031, Ribavirin, SCH 018908 | Merck Sharp & Dohme LLC | Hepatitis C, Hepatitis C, Chronic | 06/11 | 06/11 | | |
NCT01200225: An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) |
|
|
| Completed | N/A | 1155 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
| Completed | N/A | 30 | Europe | Boceprevir, Peginterferon alfa-2b and ribavirin | Azienda Ospedaliero-Universitaria di Parma | Chronic Hepatitis C | 10/13 | | | |
OPTIM, NCT01884402: Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 |
|
|
| Completed | N/A | 770 | Europe | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Hepatitis C, Chronic | 05/14 | 08/14 | | |
NCT01392742: An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin |
|
|
| Completed | N/A | 443 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 07/14 | 07/14 | | |
PEGHOPE, NCT01416610: An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy |
|
|
| Completed | N/A | 88 | Europe | | Hoffmann-La Roche | Hepatitis C, Chronic | 10/14 | 10/14 | | |
NCT02118597: An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients |
|
|
| Terminated | N/A | 19 | Europe | Boceprevir, Victrelis, Simeprevir, Olysio, Pegylated Interferon (Peginterferon) Alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 05/15 | 05/15 | | |
NCT00021632: Effects of Ribavirin on Zidovudine or Stavudine |
|
|
| Completed | N/A | 32 | US | | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Hepatitis C | | | | |
NCT01659567: A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C |
|
|
| Completed | N/A | 516 | RoW | Pegylated Interferon Alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 10/15 | 10/15 | | |
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | Europe | Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
|
|
RHACE 1, NCT02098616: Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus |
|
|
| Completed | N/A | 25 | US | DCV/ASV/BMS-791325, Fixed Dose Combination (FDC) of Daclatasvir/Asunaprevir/BMS-791325, DCV/ASV/BMS-791325 + RBV | Timothy Morgan, MD, VA Long Beach Healthcare System, National Cancer Institute (NCI), Bristol-Myers Squibb | Hepatitis C | 02/16 | 02/16 | | |
